美股异动 | 首款“口服版减肥神药”获批 诺和诺德(NVO.US)盘前涨超8%

Core Viewpoint - Novo Nordisk's oral GLP-1 weight loss drug has received FDA approval, giving it a competitive edge over Eli Lilly in the market [1] Group 1: Product Approval and Market Impact - The FDA has approved Novo Nordisk's first oral GLP-1 weight loss drug, Wegovy, which is set to launch in the U.S. in early January next year [1] - The initial cash price for Wegovy will be $149 per month [1] - Clinical data indicates that Wegovy can help patients lose up to 16.6% of their body weight and reduce cardiovascular risk [1] Group 2: Competitive Landscape - Eli Lilly's own oral weight loss drug is expected to receive approval in March next year, providing Novo Nordisk with a valuable window of opportunity to establish its market presence [1]